In present animal study, our data demonstrated SN50 effectively down-regulated TF and PAI-1 expressions in lung tissue, decreased concentrations of procoagulants (TF, PAI-1, TAT) and promoted activated protein C (APC) in BALF, and attenuated collagen III expression in pulmonary tissue, suggesting that SN50 is expected to be an effective target to attenuate hypercoagulation and fibrinolysis inhibition in ARDS. Here, TF is linked to acute respiratory distress syndrome.